The world of knee surgery is facing a critical crossroads, and it's time we shed some light on a practice that may be doing more harm than good.
Let's delve into the findings of a recent study that has left many experts scratching their heads. The research, published in the New England Journal of Medicine, followed patients for a decade after they underwent either arthroscopic knee surgery or a mere 'sham surgery' for knee pain. The results were eye-opening: the surgery provided little to no benefit and, alarmingly, was associated with accelerated osteoarthritis and higher rates of reoperation, often leading to total knee replacements.
One of the study's authors, Teppo Järvinen, an orthopedist and head of the Finnish Centre for Evidence-Based Orthopaedics, summed it up bluntly: "I don't know how I would defend this procedure at all." This statement is a stark admission, especially considering the potential long-term implications for patients.
What makes this particularly fascinating is the disparity between the study's findings and the current practice in the U.S. While arthroscopic rates in Finland have dropped by a staggering 90%, the decline in the U.S. has been much slower. A study of commercial claims revealed over 2 million meniscus surgeries from 2010 to 2020, with a mere 4% decrease each year. Most procedures were performed on women and patients in their 50s, a demographic that should give us pause.
In the traditional Medicare fee-for-service program, the number of procedures has declined from about 169,000 in 2014 to 91,000 in 2024. However, these figures do not include beneficiaries in Medicare Advantage, which covers more than half of Medicare enrollees. This gap in data highlights a potential blind spot in our understanding of the true extent of these surgeries.
Prior studies have found that such tears are common in people over 50, often resulting from wear and tear and not necessarily causing pain. Yet, the narrative that a patient's pain stems from the meniscus persists. Järvinen challenges this notion, stating, "Nothing supports the idea that a patient's pain comes from the meniscus."
Robert Brophy, director of the Orthopaedic Clinical Research Center at Washington University in St. Louis, acknowledges the growing evidence for the judicious use of this surgery. However, he notes that "many patients do benefit." This statement underscores the complexity of the issue and the need for a nuanced approach.
The practice among Brophy's peers is described as "all over the map." Data shows that surgery for meniscus tears in the Medicare population is far more common in the South than in the Northeast. This geographic disparity raises questions about the consistency and standardization of treatment across different regions.
A consensus statement released by orthopedic societies in Europe and the U.S. last summer noted that "degenerative meniscus lesions can be treated with comparable results with either non-operative (including physical therapy) or surgical approach." This statement recommends a trial of physical therapy before surgery but still endorses the operation. It's a delicate balance between conservative and surgical approaches, and one that requires careful consideration.
The Save the Meniscus Society, a concerted campaign by orthopedic specialty societies, advocates for protecting and maintaining long-term knee health through nonsurgical treatments, surgical repair, and other therapies. This initiative highlights the importance of exploring alternative approaches and the potential benefits of a more holistic treatment plan.
One inherent issue in all medical specialties is that appropriate treatment is often in the eye of the physician beholder. Specialists create the guidelines for when a treatment is in order, and financial considerations may influence that decision. In the U.S., physician payments are decided by the Relative Value Scale Update Committee, a committee of the American Medical Association composed largely of specialists. This raises questions about the potential influence of financial incentives on treatment decisions.
Arthroscopic knee surgery, which takes 30 to 60 minutes in the operating room, comes with a hefty price tag. Medicare allots on average $2,159 to $3,875 for the procedure, with patients paying 20% of the fee as coinsurance. Commercial insurers average well over twice that amount, and the charges vary widely. These costs do not include the fees of the surgeons and the anesthesiologist. It's a significant financial burden, especially when considering the potential lack of long-term benefits.
The treatment for chronic knee pain has evolved over the years. Fifty years ago, the approach was to remove the entire piece of cartilage, viewing it as a useless, vestigial piece of tissue. Today, the first-line therapy for a painful knee with degenerative tears is physical therapy and, for some, weight loss. The menu of injections includes steroids, stem cells, and plasma-rich protein, the latter two being controversial and not covered by most insurance due to inconclusive studies.
As orthopedists move away from shaving off meniscus tears, they are highlighting a newer procedure: sewing the torn cartilage back into a whole. However, this procedure is typically an option for patients under 50 with acute injuries and clean tears, and it's unclear which patients might benefit. It's a delicate balance between preserving the meniscus and the potential risks and benefits of different surgical approaches.
When all else fails, knee replacement surgery is an option, but it's also a big moneymaker for hospitals and doctors. This raises questions about the potential over-reliance on surgical interventions and the need for a more nuanced, patient-centric approach.
In conclusion, the recent study on arthroscopic knee surgery has shed light on a practice that may be doing more harm than good. The disparity between the study's findings and current practice in the U.S. highlights the need for a critical reevaluation of our approach to knee surgery. As we move forward, it's crucial to consider the long-term implications for patients, the potential influence of financial incentives, and the importance of exploring alternative, non-surgical treatments. The world of knee surgery is at a crossroads, and it's time we navigate this path with caution and a commitment to patient-centric care.
